Nuzyra net U.S. sales of $66.4 million, a 221% Y/Y increase, including $28.3 million net sales from the core commercial business, a 37% increase, and $38.1 million in revenue from the second procurement of Nuzyra under the BARDA contract.
Nuzyra (omadacycline), the company’s lead product, is a once-daily oral and intravenous antibiotic for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
The company reported an EPS loss of $(0.13), better than $(0.66) a year ago.
SG&A expenses increased to $53.8 million in Q4 FY22 from $44 million, primarily due to costs incurred in connection with the Nuzyra community expansion and travel costs due to the easing of COVID-19 restrictions.
R&D expenses were $14.3 million compared to $10.4 million a year ago due to costs for activities reimbursed under the BARDA contract and costs incurred for the Phase 2b Nontuberculous Mycobacteria study.
Guidance: Paratek expects FY23 revenue of $143-$158 million, far below the consensus of $232.02 million.
Nuzyra net U.S. sales are expected to be approximately $125.0 to $135.0 million, below the $136.8 million recorded in 2022.
Paratek had cash and cash equivalents of $34.2 million, combined with $36.1 million in cash received from BARDA for the second procurement of NUZYRA, yielded a pro forma cash and cash equivalents balance of $70.3 million sufficient to provide a cash runway into Q1 2024.
Price Action: PRTK shares are down 30.6% at $1.33 on the last check Thursday.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
